|
Active substance |
tabelecleucel |
|
Holder |
Pierre Fabre Medicament |
|
Status |
closed |
|
Indication |
Monotherapy for the treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. |
|
Public documents |
|
|
Last update |
19/07/2024 |
Ebvallo CUP-202227
Last updated on